HUTCHMED DRC Net Income
| HCM Stock | USD 15.00 0.25 1.64% |
As of the 1st of February, HUTCHMED DRC retains the market risk adjusted performance of (0.09), and Risk Adjusted Performance of (0). HUTCHMED DRC technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Please check out HUTCHMED DRC standard deviation, as well as the relationship between the maximum drawdown and kurtosis to decide if HUTCHMED DRC is priced adequately, providing market reflects its last-minute price of 15.0 per share. Given that HUTCHMED DRC has information ratio of (0.03), we strongly advise you to confirm HUTCHMED DRC's regular market performance to make sure the company can sustain itself next year.
HUTCHMED DRC's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing HUTCHMED DRC's valuation are provided below:HUTCHMED DRC does not currently have any fundamental trends for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Will Pharmaceuticals sector continue expanding? Could HUTCHMED diversify its offerings? Factors like these will boost the valuation of HUTCHMED DRC. Market participants price HUTCHMED higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every HUTCHMED DRC data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding HUTCHMED DRC requires distinguishing between market price and book value, where the latter reflects HUTCHMED's accounting equity. The concept of intrinsic value—what HUTCHMED DRC's is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push HUTCHMED DRC's price substantially above or below its fundamental value.
Please note, there is a significant difference between HUTCHMED DRC's value and its price as these two are different measures arrived at by different means. Investors typically determine if HUTCHMED DRC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, HUTCHMED DRC's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
HUTCHMED DRC 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to HUTCHMED DRC's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of HUTCHMED DRC.
| 11/03/2025 |
| 02/01/2026 |
If you would invest 0.00 in HUTCHMED DRC on November 3, 2025 and sell it all today you would earn a total of 0.00 from holding HUTCHMED DRC or generate 0.0% return on investment in HUTCHMED DRC over 90 days. HUTCHMED DRC is related to or competes with Bausch Health, Perrigo Company, Ideaya Biosciences, Supernus Pharmaceuticals, Catalyst Pharmaceuticals, Scholar Rock, and Adaptive Biotechnologies. HUTCHMED Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immuno... More
HUTCHMED DRC Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure HUTCHMED DRC's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess HUTCHMED DRC upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.03) | |||
| Maximum Drawdown | 9.3 | |||
| Value At Risk | (2.68) | |||
| Potential Upside | 2.4 |
HUTCHMED DRC Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for HUTCHMED DRC's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as HUTCHMED DRC's standard deviation. In reality, there are many statistical measures that can use HUTCHMED DRC historical prices to predict the future HUTCHMED DRC's volatility.| Risk Adjusted Performance | (0) | |||
| Jensen Alpha | (0.04) | |||
| Total Risk Alpha | (0.11) | |||
| Treynor Ratio | (0.10) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of HUTCHMED DRC's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
HUTCHMED DRC February 1, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0) | |||
| Market Risk Adjusted Performance | (0.09) | |||
| Mean Deviation | 1.33 | |||
| Coefficient Of Variation | (10,296) | |||
| Standard Deviation | 1.79 | |||
| Variance | 3.2 | |||
| Information Ratio | (0.03) | |||
| Jensen Alpha | (0.04) | |||
| Total Risk Alpha | (0.11) | |||
| Treynor Ratio | (0.10) | |||
| Maximum Drawdown | 9.3 | |||
| Value At Risk | (2.68) | |||
| Potential Upside | 2.4 | |||
| Skewness | 0.9358 | |||
| Kurtosis | 2.4 |
HUTCHMED DRC Backtested Returns
HUTCHMED DRC holds Efficiency (Sharpe) Ratio of close to zero, which attests that the entity had a close to zero % return per unit of volatility over the last 3 months. HUTCHMED DRC exposes twenty-four different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check out HUTCHMED DRC's market risk adjusted performance of (0.09), and Risk Adjusted Performance of (0) to validate the risk estimate we provide. The company retains a Market Volatility (i.e., Beta) of 0.27, which attests to not very significant fluctuations relative to the market. As returns on the market increase, HUTCHMED DRC's returns are expected to increase less than the market. However, during the bear market, the loss of holding HUTCHMED DRC is expected to be smaller as well. At this point, HUTCHMED DRC has a negative expected return of -0.0174%. Please make sure to check out HUTCHMED DRC's kurtosis, as well as the relationship between the day median price and period momentum indicator , to decide if HUTCHMED DRC performance from the past will be repeated at some future point.
Auto-correlation | -0.81 |
Excellent reverse predictability
HUTCHMED DRC has excellent reverse predictability. Overlapping area represents the amount of predictability between HUTCHMED DRC time series from 3rd of November 2025 to 18th of December 2025 and 18th of December 2025 to 1st of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of HUTCHMED DRC price movement. The serial correlation of -0.81 indicates that around 81.0% of current HUTCHMED DRC price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.81 | |
| Spearman Rank Test | -0.72 | |
| Residual Average | 0.0 | |
| Price Variance | 0.85 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, HUTCHMED DRC reported net income of 37.73 M. This is 88.94% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The net income for all United States stocks is 93.39% higher than that of the company.
HUTCHMED Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses HUTCHMED DRC's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of HUTCHMED DRC could also be used in its relative valuation, which is a method of valuing HUTCHMED DRC by comparing valuation metrics of similar companies.HUTCHMED DRC is currently under evaluation in net income category among its peers.
HUTCHMED Fundamentals
| Return On Equity | 0.47 | ||||
| Return On Asset | -0.0081 | ||||
| Profit Margin | 0.78 % | ||||
| Operating Margin | (0.01) % | ||||
| Current Valuation | 1.33 B | ||||
| Shares Outstanding | 171.9 M | ||||
| Shares Owned By Institutions | 3.38 % | ||||
| Number Of Shares Shorted | 332.42 K | ||||
| Price To Earning | 335.94 X | ||||
| Price To Book | 2.12 X | ||||
| Price To Sales | 4.57 X | ||||
| Revenue | 630.2 M | ||||
| Gross Profit | 53.76 M | ||||
| EBITDA | 14.11 M | ||||
| Net Income | 37.73 M | ||||
| Cash And Equivalents | 829.71 M | ||||
| Cash Per Share | 4.91 X | ||||
| Total Debt | 89.82 M | ||||
| Current Ratio | 3.18 X | ||||
| Book Value Per Share | 1.43 X | ||||
| Cash Flow From Operations | 497 K | ||||
| Short Ratio | 6.39 X | ||||
| Earnings Per Share | 2.65 X | ||||
| Target Price | 21.1 | ||||
| Number Of Employees | 1.78 K | ||||
| Beta | 0.5 | ||||
| Market Capitalization | 2.75 B | ||||
| Total Asset | 1.27 B | ||||
| Retained Earnings | (833.17 M) | ||||
| Working Capital | 689.99 M | ||||
| Current Asset | 187.47 M | ||||
| Current Liabilities | 96.7 M | ||||
| Net Asset | 1.27 B |
About HUTCHMED DRC Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze HUTCHMED DRC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of HUTCHMED DRC using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of HUTCHMED DRC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out To learn how to invest in HUTCHMED Stock, please use our How to Invest in HUTCHMED DRC guide.You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Will Pharmaceuticals sector continue expanding? Could HUTCHMED diversify its offerings? Factors like these will boost the valuation of HUTCHMED DRC. Market participants price HUTCHMED higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every HUTCHMED DRC data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding HUTCHMED DRC requires distinguishing between market price and book value, where the latter reflects HUTCHMED's accounting equity. The concept of intrinsic value—what HUTCHMED DRC's is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push HUTCHMED DRC's price substantially above or below its fundamental value.
Please note, there is a significant difference between HUTCHMED DRC's value and its price as these two are different measures arrived at by different means. Investors typically determine if HUTCHMED DRC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, HUTCHMED DRC's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.